AR-V7 and prostate cancer: The watershed for treatment selection?

被引：49

作者：

Ciccarese, Chiara ^{[1
]}

Santoni, Matteo ^{[2
]}

Brunelli, Matteo ^{[3
]}

Buti, Sebastiano ^{[4
]}

Modena, Alessandra ^{[1
]}

Nabissi, Massimo ^{[5
]}

Artibani, Walter ^{[6
]}

Martignoni, Guido ^{[3
]}

Montironi, Rodolfo ^{[7
]}

Tortora, Giampaolo ^{[1
]}

Massari, Francesco ^{[1
]}

机构：

[1] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, Ple LA Scuro 10, I-37100 Verona, Italy

[2] Univ Marche Reg, Med Oncol, AOU Osped Riuniti, Polytech, Ancona, Italy

[3] Univ Verona, AOUI, Dept Pathol & Diagnost, I-37100 Verona, Italy

[4] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[5] Univ Camerino, Sch Pharm, Expt Med Sect, I-62032 Camerino, Italy

[6] Univ Verona, Azienda Osped Univ Integrata, Urol Clin, Dept Oncol & Surg Sci, I-37100 Verona, Italy

[7] Polytech Univ Marche Reg, Sch Med, AOU Osped Riuniti, Sect Pathol Anat, Ancona, Italy

来源：

CANCER TREATMENT REVIEWS | 2016年 / 43卷

关键词：

Prostate cancer; Androgen receptor; Splice variant; AR-V7; Prognostic role; Anti-androgens sensitivity; Taxane sensitivity; ANDROGEN RECEPTOR-ACTIVITY; SPLICE VARIANTS; DNA-BINDING; INCREASED SURVIVAL; STEROID-BINDING; SMALL-MOLECULE; HINGE REGION; TARGET GENES; RESISTANT; ENZALUTAMIDE;

D O I：

10.1016/j.ctrv.2015.12.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The androgen receptor (AR) plays a key role in progression to metastatic castration-resistant prostate cancer (mCRPC). Despite the recent progress in targeting persistent AR activity with the next generation hormonal therapies (abiraterone acetate and enzalutamide), resistance to these agents limits therapeutic efficacy for many patients. Several explanations for response and/or resistance to abiraterone acetate and enzalutamide are emerging, but growing interest is focusing on importance of AR splice variants (AR-Vs) and in particular of AR-V7. Increasing evidences highlight the concept that variant expression could be used as a potential predictive biomarker and a therapeutic target in advanced prostate cancer. Therefore, understanding the mechanisms of treatment resistance or sensitivity can help to achieve a more effective management of mCRPC, increasing clinical outcomes and representing a promising and engaging area of prostate cancer research. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：27 / 35

页数：9

共 87 条

[1] Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Andersen, Raymond J.
Mawji, Nasrin R.
Wang, Jun
Wang, Gang
Haile, Simon
Myung, Jae-Kyung
Watt, Kate
Tam, Teresa
Yang, Yu Chi
Banuelos, Carmen A.
Williams, David E.
McEwan, Iain J.
Wang, Yuzhou
Sadar, Marianne D.
[J]. CANCER CELL, 2010, 17 (06) : 535 - 546
[2] [Anonymous], ONCOTARGET
[3] Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Antonarakis, Emmanuel S.
Lu, Changxue
Luber, Brandon
Wang, Hao
Chen, Yan
Nakazawa, Mary
Nadal, Rosa
Paller, Channing J.
Denmeade, Samuel R.
Carducci, Michael A.
Eisenberger, Mario A.
Luo, Jun
[J]. JAMA ONCOLOGY, 2015, 1 (05) : 582 - 591
[4] AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, Emmanuel S.
Lu, Changxue
Wang, Hao
Luber, Brandon
Nakazawa, Mary
Roeser, Jeffrey C.
Chen, Yan
Mohammad, Tabrez A.
Chen, Yidong
Fedor, Helen L.
Lotan, Tamara L.
Zheng, Qizhi
De Marzo, Angelo M.
Isaacs, John T.
Isaacs, William B.
Nadal, Rosa
Paller, Channing J.
Denmeade, Samuel R.
Carducci, Michael A.
Eisenberger, Mario A.
Luo, Jun
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) : 1028 - 1038
[5] Bambury RM., 2015, Urol Oncol
[6] Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
[7] Bevan CL, 1999, MOL CELL BIOL, V19, P8383
[8] The role of epithelial plasticity in prostate cancer dissemination and treatment resistance
Bitting, Rhonda L.
Schaeffer, Daneen
Somarelli, Jason A.
Garcia-Blanco, Mariano A.
Armstrong, Andrew J.
[J]. CANCER AND METASTASIS REVIEWS, 2014, 33 (2-3) : 441 - 468
[9] Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
Cao, Bo
Qi, Yanfeng
Zhang, Guanyi
Xu, Duo
Zhan, Yang
Alvarez, Xavier
Guo, Zhiyong
Fu, Xueqi
Plymate, Stephen R.
Sartor, Oliver
Zhang, Haitao
Dong, Yan
[J]. ONCOTARGET, 2014, 5 (06) : 1646 - 1656
[10] Constitutive activation of the androgen receptor by a point mutation in the hinge region:: A new mechanism for androgen-independent growth in prostate cancer
Céraline, J
Cruchant, MD
Erdmann, E
Erbs, P
Kurtz, JE
Duclos, B
Jacqmin, D
Chopin, D
Bergerat, JP
[J]. INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (01) : 152 - 157

← 1 2 3 4 5 6 7 8 9 →